Clinical Trial Update: Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluated the efficacy of imatinib mesylate in hypereosinophilic syndromes and has completed, reporting efficacy signals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Leukemia
• Hypereosinophilic Syndrome
• Idiopathic Hypereosinophilia

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: Northern Italy Leukemia Group | Conditions: Hypereosinophilic Syndrome, Chronic Eosinophilic Leukemia | Phase 2 | Status: COMPLETED